© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The number of days to an undetectable viral load dropped by nearly two weeks, but there’s more work to do.
The rapid treatment era is bringing some real rewards for people living with HIV.
The woman has had an undetectable viral load and a normal CD4 count for more than 12 years after stopping antiretroviral therapy.
Switching to an integrase inhibitors is not tied to gain in bad fat, according to recent study.
People with untreated HIV in a recent study had signs of faster cell aging, which treatment reduced but did not eliminate.
While people with HIV have a higher rate of early Alzheimer’s than those without the virus, treatment appears to eliminate this excess risk.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
Whether for treatment or prevention, women’s interest in injectable antiretrovirals varied based on their relationship with injection.
COVID-19, HIV vaccines, cure news and long-acting injectables stood out among the top HIV treatment stories of the year.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
A new long-acting injectables HIV drug shows promise in monkey study.
Overweight and obesity are linked to a host of health problems.
Some HIV meds are linked to weight gain, but we don’t yet know why.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.